Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma
Programmed cell death ligand 1 (PD-L1) inhibitors are commonly used in treating advanced-stage urothelial carcinoma (UC). Therefore, this study evaluated the relationship between PD-L1 expression in circulating tumor cells (CTCs) and treatment response to PD-L1 inhibitors using blood samples collect...
Main Authors: | Pei-Jhang Chiang, Ting Xu, Tai-Lung Cha, Yi-Ta Tsai, Shu-Yu Liu, Sheng-Tang Wu, En Meng, Chih-Wei Tsao, Chien-Chang Kao, Chin-Li Chen, Guang-Huan Sun, Dah-Shyong Yu, Sun-Yran Chang, Ming-Hsin Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Biology |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-7737/10/7/674 |
Similar Items
-
Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma
by: Magdalena Zajac, et al.
Published: (2019-09-01) -
Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01) -
Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC)
by: Sonja Bergmann, et al.
Published: (2020-01-01) -
Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
by: Giandomenico Roviello, et al.
Published: (2021-08-01) -
Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients
by: Veronika Weyerer, et al.
Published: (2021-05-01)